$BIOA News

Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target

BioAge Labs' Lead Drug Faces Uncertain Path as Data Looms, UBS Says

UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Roth Capital Reiterates Buy on Bioage Labs, Maintains $25 Price Target

BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema

BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target

BioAge Labs Doses First Patient In Its Phsae 2 Study Of BGE-102 To Treat Diabetic Macular Edema

BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off

BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

Bioage Labs Q2 EPS $(0.58) Beats $(0.60) Estimate, Sales $2.451M Beat $1.920M Estimate

BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target

BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?

Needham Maintains Buy on Bioage Labs, Lowers Price Target to $35

More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?